And the best medical device innovation of 2022 goes to…

The Cala Health Cala Trio [Image courtesy of Cala Health]

The Galien Foundation last night honored Cala Health’s Cala Trio essential tremor treatment wearable as 2022’s best medical device innovation.

The foundation describes its Prix Galien awards as the global equivalent of the Nobel Prize for the life science industry.

The Cala Trio offers a non-invasive method to send signals to the brain to treat essential tremor rather than deep-brain stimulation. It was one of two dozen devices that were nominees in this year’s competition. (Here is Medical Design & Outsourcing‘s roundup of the full 24.)

More about Cala Health and its Cala Trio

MDO recently interviewed Cala Health co-founder and Chief Scientific Officer Kate Rosenbluth and CEO Renee Ryan about the creation of the technology. The Cala Trio has FDA clearance as an external upper limb tremor stimulator, available by…

Read more
  • 0

Exscientia raises $225M for drug discovery AI

AI-powered drug discovery company Exscientia announced that it completed a $225 Series D funding round.

SoftBank Vision Fund 2 led the funding round, while previous lead investors, Novo Holdings and funds managed by Blackrock, contributed. Other investors included Mubadala Investment Company, Farallon Capital, Casdin Capital, GT Healthcare Capital, Marshall Wace, Pivotal bioVenture Partners, Laurion Capital, Hongkou and Bristol-Myers Squibb, according to a news release.

Additionally, SoftBank is providing Exscientia with a further $300 million equity commitment available to be drawn by the Oxford, England-based company at its discretion.

Exscientia utilizes AI to engineer new medicines, with the technology working in target identification, drug design and patient selection. The company has put two fully AI-designed drugs into clinical trials and has more than 20 active programs in its pipeline.

The company plans to use the funds raised in the roun…

Read more
  • 0